myTomorrows is a global health technology company that helps patients and physicians navigate and access pre-approval treatments, such as clinical trials and expanded access programs. Pulse 2.0 interviewed myTomorrows CEO Dr. Michel van Harten to learn more.
Dr. Michel van Harten’s Background
Could you tell me more about your background? Dr. van Harten said:
“I’ve always been driven by both a commitment to clinical care and an interest in how healthcare systems function. I earned both my BSc in Economics and my Medical Degree at the University of Amsterdam, which gave me a strong foundation in understanding not only how care is delivered, but also the broader dynamics that shape patient access.”
“Early in my career, I had the opportunity to conduct research at Weill Cornell Medical College and Memorial Sloan Kettering in New York City, two institutions at the forefront of medical innovation. Those experiences fueled my desire to work directly with patients, and I went on to practice as a physician at the Antoni van Leeuwenhoek Hospital, a leading cancer institute in Amsterdam. Over the years, I’ve gained more than 18 years of experience and developed a deep understanding of the challenges faced by both patients and physicians.”
“When I joined myTomorrows in 2017, I had spent years treating patients with complex and often terminal cancers. I saw firsthand the emotional and physical toll these diagnoses take on patients and their families. I also experienced the immense difficulty of navigating the fragmented and time-sensitive landscape of treatment options when standard therapies were no longer effective.”
“That gap between patient needs and the difficulty of accessing options is what brought me to myTomorrows, to help make it easier for patients and their physicians to reach emerging therapies.”
Formation Of The Company
How did the idea for the company come together? Dr. van Harten shared:
“myTomorrows began with our founder, Ronald Brus, MD. After years leading drug development in pharma, he saw firsthand how challenging it was to access emerging treatments when his father was diagnosed with cancer. That experience led him to create myTomorrows, with the goal of making it easier for patients to find and access treatments.”
“In the early days, the company focused solely on expanded access programs – which give eligible patients access to experimental treatments when clinical trials aren’t an option. But in 2020, we shifted to a broader model, adding clinical trial recruitment and real-world data (RWD) capabilities, so we could support all access pathways worldwide for patients, physicians, and BioPharma companies.”
Notable Memory
What has been one of your notable memories while working at the company? Dr. van Harten reflected:
“One moment that has stayed with me involved a two-year-old patient who developed a life-threatening complication after a stem cell transplant. Their physician contacted us urgently to explore whether an investigational therapy available via expanded access might be an option. Our team moved quickly, coordinating with the sponsor, regulators and the treating hospital. Within just a few days, the medicine was administered and the child survived.”
“For me, that experience captures exactly why our work is so important. It is a powerful reminder that behind every program, every process and every technology we build, there is a real person whose life may depend on timely access to treatment.”
Core Products
What are the company’s core products and features? Dr. van Harten explained:
- A unified access hub: Leading companies rely on us for faster trial recruitment, expanded access management, and real-world data that informs regulatory submissions. Our multi-stakeholder platform brings together clinical trials and expanded access programs in one place, serving patients, BioPharma companies, physicians, trial sites and patient advocacy groups.
- Human expertise:
- For patient recruitment, our multilingual Patient Navigation team provides personalized support across global time zones, backed by client program managers who ensure a smooth and coordinated experience.
- For Expanded Access and RWD, our site, program, and real-world data management teams provide end-to-end oversight, with regulatory affairs specialists ensuring each project meets the necessary requirements.
- Smarter trial recruitment: AI-powered matching reduces pre-screening time by up to 90%, giving physicians and trial sites quicker visibility into patient eligibility.
- Compliance-ready access pathways: We provide transparent information on relevant trials and, where appropriate, expanded access programs. Seamless request initiation ensures every access route is compliant and efficient.
Challenges Faced
Have you faced any challenges in your sector of work recently? Dr. van Harten acknowledged:
“The first challenge has been around the rapid evolution of data privacy requirements and the growing focus on AI regulation and ethics. Working with sensitive patient information demands the highest standards, so we made a deliberate decision to lead rather than follow. We adopted full regulatory compliance frameworks and pursued the certifications needed to ensure our platform meets rigorous global standards. This has given our clients, partners and users strong confidence that their data is handled securely, ethically and transparently.”
“The second challenge relates to the slow pace of technology and AI adoption within traditional healthcare environments. Many sites and physicians are still navigating how to integrate new tools into their daily workflows – and in many cases are looking for guidance from places of work on how to bring in new ways of working. To overcome this, we invest heavily in engaging the medical community directly. Our teams work hand-in-hand with physicians and study teams to demonstrate the platform, show how it can drive efficiency and offer support on integrations into existing processes. This practical, partnership-driven approach has been crucial in driving adoption and ensuring our technology creates real value at the point of care.”
Evolution Of The Company’s Technology
How has the company’s technology evolved since launching? Dr. van Harten noted:
“Our technology has evolved exponentially since we first launched. We’ve always had a tech-first mindset, with an in-house engineering team that built our proprietary platform from the ground up. But over the past three years, especially with advancements in AI and large language models (LLMs), we’ve been able to significantly accelerate our capabilities and introduce efficiencies that make the platform faster, smarter, and more intuitive for users.”
“Today, we offer one of the fastest and most accurate AI-driven trial-matching engines in the market. We’ve also expanded the platform with workflow integrations that allow partners and clinical sites to use our tools directly within their existing systems. And through APIs, we can provide scalable solutions for organizations of any size, enabling them to search treatment options for patients at volume rather than case-by-case.”
“These advancements mean that what once required manual effort can now be done in seconds, ultimately helping patients, physicians, and BioPharma partners access the right information and act, far more efficiently.”
Significant Milestones
What have been some of the company’s most significant milestones? Dr. van Harten cited:
“We’ve reached several important milestones in the past few years that have shaped our trajectory. One of the most transformative was the launch of our AI-powered clinical trial search tool, originally called TrialSearch AI, in April 2023. From that point, we’ve advanced our capabilities rapidly, and as of early 2025, we now deliver an unparalleled 98% precision accuracy. This development fundamentally changed how quickly and accurately patients and physicians can identify potential treatment options.”
“Another major milestone was the signing of several large pharmaceutical clients in 2024 and 2025. These partnerships marked an important credibility threshold for us, demonstrating industry confidence in our ability to support both clinical trial recruitment and expanded access at scale.”
“The growth equity investment by Avego Healthcare Capital in 2025 represented a pivotal moment for the company. It gives us the resources to accelerate our global expansion, deepen our technology capabilities, and strengthen our role as the leading platform for pre-approval access.”
Customer Success Stories
Can you share any specific customer success stories? Dr. van Harten highlighted:
“An example of success is our collaboration with the ALS Association in the United States. Together, we have been working to accelerate recruitment for ALS clinical trials, an area where time and access are especially critical.”
“By combining the ALS Association’s trusted patient community with myTomorrows’ AI-powered trial matching and Patient Navigation support, we have been able to identify and pre-screen eligible patients far more efficiently than traditional approaches. This significantly reduced the burden on clinical sites while helping patients quickly understand whether a trial might be an option for them.”
“The result was faster enrollment, improved trial visibility, and a better experience for patients and physicians alike. It demonstrated how partnerships between patient organizations and technology-enabled access platforms can meaningfully speed up research and bring potential treatments closer to people who urgently need them.”
Funding
Are you able to discuss funding? Dr. van Harten revealed:
“In November, we announced new equity growth funding of €25 million/$29 million. This was a pivotal moment for myTomorrows and an important step in our goal to fix the broken access system. Our investor Avego Healthcare Capital brings deep expertise in life sciences, clinical development and broader patient access. Their experience in supporting companies that develop and commercialize innovative healthcare solutions makes them the ideal partner at this stage of our growth.”
“Over the past four years, we have grown our revenue by 500%, and we expect to deliver similar growth over the next four years as demand for pre-approval access solutions continues to accelerate.”
“This investment allows us to accelerate and scale our impact globally. We’re working to expand our reach beyond the 134 countries we already serve, advance our AI-powered technology to make search and discovery of emerging therapies even faster and more precise and strengthen our industry partnerships to optimize and streamline patient recruitment and expanded access programs. We are also growing our real-world data capabilities so that programs can generate valuable insights for regulators and to inform their drug development roadmaps. Finally, we’ve invested in end-to-end patient support, ensuring that each patient journey is as smooth as possible.”
“We estimate our total addressable market at roughly 35 billion euros. Looking at this from a needs-based perspective, there are around 300 million people worldwide living with rare diseases who often have limited or no approved treatment options. At the same time, there are approximately 10,000 therapies currently in development or awaiting approval.”
“Our goal is to bridge that gap by helping patients and physicians identify and access potential treatment avenues before those therapies reach the market.”
Differentiation From The Competition
What differentiates the company from its competition? Dr. van Harten affirmed:
“What sets myTomorrows apart is that we are the only platform that connects patients to all pre-approval treatment pathways in one place. Whether through clinical trials or expanded access, we help patients and their physicians identify every possible option and support them in accessing it.”
“Our AI-powered platform accelerates this process by pre-screening patients for trial eligibility and sending sites only qualified referrals, reducing their workload. And when a clinical trial is not an option, we can work with physicians and sponsors to request expanded access so patients in critical need are not left without alternatives.”
“For BioPharma, we offer a fully integrated solution that combines clinical trial recruitment and expanded access within a single framework. This ensures no patients are lost between pathways, trial enrolment is optimised, and valuable opportunities to generate real-world data are maximised. The evidence collected through our expanded access programs supports regulatory decision-making and informs product strategy, which can be especially important in areas such as rare disease and oncology.”
“In short, myTomorrows provides the only end-to-end access pipeline that meets patient needs, supports physicians, and helps BioPharma bring new therapies to patients faster.”
Future Company Goals
What are some of the company’s future goals? Dr. van Harten concluded:
“We are already becoming the default gateway for pre-approval treatments; however, we see a world where myTomorrows is top of mind when the standard treatment of care for patients has run out. We’re already integrating into healthcare systems worldwide, but we can go further. Inequity and inequality remain a major barrier to patient care globally, and by working in tandem with leading industry innovators, our goal is to close that gap and ensure that every patient, regardless of where they live, has equal access to potential options.”
